NCT04592198View on ClinicalTrials.gov

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
DRUG

Palonosetron Hydrochloride Buccal Film 0.25 Mg

Dose equal to the iv control

DRUG

Palonosetron Hydrochloride Buccal Film 0.5 Mg

Dose twice that of iv control

DRUG

Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution

iv control

Trial Locations (7)

15063

Monongahela Valley Hospital/ Regional Cancer Center, Monongahela

17325

Gettysburg Cancer Center, Gettysburg

29406

Charleston Oncology, Charleston

34474

Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala

39401

Hattiesburg Clinic Hematology/Oncology, Hattiesburg

60076

Edward H. Kaplan MD & Associates, Skokie

92801

Pacific Cancer Medical Center, Inc., Anaheim

All Listed Sponsors
lead

Xiamen LP Pharmaceutical Co., Ltd

INDUSTRY

NCT04592198 - Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting | Biotech Hunter | Biotech Hunter